Menu Search
Equities

Perimeter Medical Imaging AI Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4PC:FRA

Perimeter Medical Imaging AI Inc

Actions
  • Price (EUR)0.138
  • Today's Change-0.013 / -8.31%
  • Shares traded10.00k
  • 1 Year change-70.64%
  • Beta1.4766
Data delayed at least 15 minutes, as of Feb 06 2026 15:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Perimeter Medical Imaging AI, Inc. medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The Company’s Perimeter Optical Coherence Tomography (OCT) system, which provides cross-sectional, real-time margin visualization of tissue microstructures during surgical procedures. The OCT imaging system includes an intraoperative device for automated scanning of the specimen that provides a rapid subsurface map of up to 10 centimeters (cm) by 10 cm surface area; a specimen-handling consumable designed to hold and maintain orientation of the specimen, and an image library and training set. Its S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. It is focused on its machine learning tools and artificial intelligence (AI) technology, called ImgAssist AI, through clinical development under its ATLAS AI project.

  • Revenue in CAD (TTM)2.58m
  • Net income in CAD-19.67m
  • Incorporated2020
  • Employees56.00
  • Location
    Perimeter Medical Imaging AI Inc555 Richmond Street W., Suite 511TORONTO M5V 3B1CanadaCAN
  • Phone+1 (214) 845-5154
  • Websitehttps://ir.perimetermed.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.